Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus, MMF, and Bortezomib for GVHD Prophylaxis After Stem Cell Transplant
NCT00548717Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2007
- Primary completion
- Sep 2013
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in graft-versus-host disease (GVHD), sponsored by Dana-Farber Cancer Institute. Started Oct 2007; status: terminated.
02
Drugs
bortezomib
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00548717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00548717.